Searching across hundreds of databases
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
Integrated Clinical Trials is a virtual database currently indexing clinical trials from: EU Clinical Trials Register and ClinicalTrials.gov.
(last updated: Nov 28, 2022)
Clinical Trials Information| Database | Title | Recruitment | Conditions | Intervention | Sponsored By | Gender | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Clinicaltrials.gov | Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma | Completed | Melanoma (Skin) | Biological, Other, Other, Other, Other, Procedure, Procedure, Procedure - sargramostim, immunoenzyme technique, immunohistochemistry staining method, immunologic technique, laboratory biomarker analysis, biopsy, cryosurgery, radiofrequency ablation | Mayo Clinic, National Cancer Institute (NCI), Other, NIH | 18 Years - 120 Years | Phase 1 | Interventional | RATIONALE: Radiofrequency therapy and radiofrequency ablation use a high-frequency electric current to kill tumor cells. Radiofrequency therapy can also cause the body to produce heat-shock proteins which may help kill more tumor cells. Cryotherapy kills tumor cells by freezing them. It is not yet known whether heat-shock proteins caused by radiofrequency therapy given together with radiofrequency ablation or cryotherapy is more effective in treating stage IV melanoma than radiofrequency therapy-induced heat-shock proteins alone. PURPOSE: This randomized clinical trial is studying the side effects of radiofrequency therapy-induced endogenous heat-shock proteins when given alone or together with radiofrequency ablation or cryotherapy in treating patients with stage IV melanoma. | ||
Clinicaltrials.gov | Breath Test for Women Receiving Tamoxifen in the Prevention or Treatment of Breast Cancer | Terminated | Breast Cancer | Drug, Drug, Other, Other, Other, Other, Procedure - dextromethorphan hydrobromide, tamoxifen citrate, high performance liquid chromatography, laboratory biomarker analysis, pharmacogenomic studies, pharmacological study, fluorescence imaging | Mayo Clinic, National Cancer Institute (NCI), Other, NIH | Female | 18 Years - 120 Years | Observational | RATIONALE: A breath test that measures enzymes may be effective in identifying women in whom tamoxifen may not be effective. PURPOSE: This clinical trial is studying a breath test to see how well it works in women receiving tamoxifen for the prevention or treatment of breast cancer. | ||
|
Clinicaltrials.gov | Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma | Completed | Melanoma (Skin) | Biological, Other, Other, Other - B7-DC cross-linking antibody rHIgM12B7, flow cytometry, immunologic technique, laboratory biomarker analysis | Mayo Clinic, National Cancer Institute (NCI), Other, NIH | 18 Years - 120 Years | Phase 1 | Interventional | RATIONALE: Monoclonal antibodies can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This clinical trial is studying the side effects and best dose of a monoclonal antibody in treating patients with stage IV melanoma. | ||
|
Clinicaltrials.gov | Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery | Completed | Breast Cancer, Cardiac Toxicity | Biological, Drug, Drug, Drug, Drug, Genetic, Genetic, Other, Other, Other, Procedure, Procedure - trastuzumab, cyclophosphamide, doxorubicin hydrochloride, lapatinib ditosylate, paclitaxel, gene expression analysis, reverse transcriptase-polymerase chain reaction, fluorophotometry, laboratory biomarker analysis, mass spectrometry, adjuvant therapy, quality-of-life assessment | Mayo Clinic, National Cancer Institute (NCI), Other, NIH | 18 Years - 120 Years | Phase 2 | Interventional | RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy together with trastuzumab and lapatinib after surgery may kill any tumor cells that remain after surgery. PURPOSE: This randomized phase II trial is studying the side effects and how well giving doxorubicin together with cyclophosphamide followed by trastuzumab, paclitaxel, and lapatinib works in treating patients with early-stage HER2-positive breast cancer that has been removed by surgery. | ||
|
Clinicaltrials.gov | Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to External-Beam Radiation Therapy | Terminated | Prostate Cancer | Biological, Drug, Genetic, Other, Radiation - Ad5-CMV-NIS, liothyronine sodium, reverse transcriptase-polymerase chain reaction, laboratory biomarker analysis, iodine I 131 | Mayo Clinic, National Cancer Institute (NCI), Other, NIH | Male | 18 Years - 120 Years | Phase 1 | Interventional | RATIONALE: Radioactive drugs, such as radioactive iodine, may carry radiation directly to tumor cells and not harm normal cells. Placing a gene called Ad5CMV-NIS in prostate cancer cells may help the prostate cells take in more radioactive iodine and thus kill the cancer cells. Drugs, such as liothyronine sodium, may protect the thyroid from the side effects of radioactive iodine. PURPOSE: This phase I trial is studying the side effects and best dose of gene therapy given together with radioactive iodine in treating patients with locally recurrent prostate cancer that did not respond to external-beam radiation therapy. | |
|
Clinicaltrials.gov | Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma | Active, not recruiting | Lymphoma | Biological, Biological, Drug, Drug, Drug, Drug, Drug, Genetic, Other - pegfilgrastim, rituximab, cyclophosphamide, doxorubicin hydrochloride, lenalidomide, prednisone, vincristine sulfate, polymorphism analysis, laboratory biomarker analysis | Mayo Clinic, National Cancer Institute (NCI), Other, NIH | 18 Years - 120 Years | Phase 1/Phase 2 | Interventional | RATIONALE: Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide together with rituximab and combination chemotherapy may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of lenalidomide when given together with rituximab and combination chemotherapy and to see how well they work in treating patients with newly diagnosed stage II, stage III, or stage IV diffuse large cell or follicular B-cell lymphoma. | ||
|
Clinicaltrials.gov | 3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx | Completed | Head and Neck Cancer | Biological, Drug, Genetic, Other, Other, Other, Radiation, Radiation - cetuximab, cisplatin, TdT-mediated dUTP nick end labeling assay, 3'-deoxy-3'-[18F]fluorothymidine, immunohistochemistry staining method, laboratory biomarker analysis, fludeoxyglucose F 18, radiation therapy | Mayo Clinic, National Cancer Institute (NCI), Other, NIH | 18 Years - 120 Years | Early Phase 1 | Interventional | RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-[18F] fluorothymidine (FLT) and fludeoxyglucose F 18 (FDG) PET scans, may help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This pilot trial is studying FLT and FDG PET scans to see how well they evaluate response to cetuximab, cisplatin, and radiation therapy in patients with advanced cancer of the oropharynx, larynx, or hypopharynx. | ||
|
Clinicaltrials.gov | Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline | Active, not recruiting | Breast Cancer, Depression, Hot Flashes, Psychosocial Effects of Cancer and Its Treatment | Drug, Drug, Drug, Drug, Drug, Drug, Genetic, Other, Other, Other, Procedure - citalopram hydrobromide, escitalopram oxalate, gabapentin, sertraline hydrochloride, tamoxifen citrate, venlafaxine, molecular genetic technique, high performance liquid chromatography, laboratory biomarker analysis, pharmacological study, adjuvant therapy | Mayo Clinic, National Cancer Institute (NCI), Other, NIH | 18 Years - 120 Years | Observational | RATIONALE: Studying samples of blood in the laboratory from patients receiving tamoxifen may help doctors learn more about the effects of other drugs on the level of tamoxifen in the blood. PURPOSE: This clinical trial is studying levels of tamoxifen in the blood of women with breast cancer and in women at high risk of breast cancer who are receiving tamoxifen together with venlafaxine, citalopram, escitalopram, gabapentin, or sertraline. | |||
|
Clinicaltrials.gov | Studying the Effect of Freeze-Dried Table Grape Powder on Blood Estrogen Levels in Postmenopausal Women | Completed | Breast Cancer | Dietary Supplement, Other, Other - standardized freeze-dried table grape powder, laboratory biomarker analysis, pharmacological study | Mayo Clinic, National Cancer Institute (NCI), Other, NIH | Female | 18 Years - 120 Years | Observational | RATIONALE: Estrogen can cause the growth of breast cancer cells. Studying samples of blood and urine in the laboratory from participants receiving freeze-dried table grape powder may help doctors understand the effect of this drug on blood estrogen levels. PURPOSE: This clinical trial is studying the effect of freeze-dried table grape powder on blood estrogen levels in postmenopausal women. | ||
|
Clinicaltrials.gov | Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer | Completed | Ovarian Cancer, Primary Peritoneal Cavity Cancer | Biological, Biological, Genetic, Other - carcinoembryonic antigen-expressing measles virus, oncolytic measles virus encoding thyroidal sodium iodide symporter, reverse transcriptase-polymerase chain reaction, laboratory biomarker analysis | Mayo Clinic, National Cancer Institute (NCI), Other, NIH | Female | 18 Years - 120 Years | Phase 1 | Interventional | RATIONALE: A gene-modified virus may be able to kill tumor cells without damaging normal cells. PURPOSE: This phase I trial is studying the side effects and best dose of an attenuated oncolytic measles virus therapy and oncolytic virus therapy in treating patients with progressive, recurrent, or refractory ovarian epithelial cancer or primary peritoneal cancer (measles virus vaccine therapy study closed as of 06/02/2008). |
Welcome to the RRID Resources search. From here you can search through a compilation of resources used by RRID and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that RRID has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on RRID then you can log in from here to get additional features in RRID such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into RRID you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
